Kinetic resolution of a b-adrenolytic drug with the use of lipases as enantioselective biocatalysts
Introduction
Cardiovascular diseases and heart diseases, also known as cardiological diseases, are the most common cause of death in developed countries, including Poland. Additionally, cardiovascular diseases are the most widespread group of diseases not only among the elderly. The causes of cardiovascular problems are diverse, which is why medicines used to fight them belong to many groups. The most common cardiological diseases are: arterial hypertension, ischaemic heart disease, arrhythmias, or heart failure. The treatment strategies of these diseases consist of the use of antihypertensive drugs, i.e. those that lower blood pressure, drugs that improve heart function, operate antiarrhythmics, or change blood properties (1) .
Propranolol belongs to the b-adrenergic receptor antagonists (b-blockers) class, which make up an important class of drugs widely used in the treatment of hypertension and cardiovascular disorders (2) (3) (4) (5) . Although propranolol is one of the oldest non-selective beta receptor blocking agents, it has well known physical and chemical properties. Hence it can be use in a comparative study of the catalytic activity of different enzymes in biocatalysis reactions. Because b-blockers have an asymmetric carbon atom in their structure, they occur in two enantiomeric forms. Although the two enantiomers of b-blockers feature the same chemical and physical properties in an achiral environment, they differ in pharmacological activity. It has been reported by many studies that only the S-enantiomer of b-blockers has the desired therapeutic effect, whereas the administration of the racemate may cause dangerous side effects, such as bronchoconstriction or diabetes (6) (7) (8) (9) . Nevertheless, b-blockers are still commercially available and mainly used in medicine as racemates.
The main aim of the study herein was to obtain enantiomerically pure (S)-propranolol acetate, which is responsible for the therapeutic effect. Additionally, enzyme screening and reaction medium selection were performed to select the best reaction conditions. The chiral compounds obtained as a result of enantioselective acetylation of (R,S)-propranolol were analysed using chiral stationary phases and UPLC-MS/MS system. Moreover, to optimise the chiral chromatographic conditions, the type of stationary phase and mobile phase composition of the chromatographic process were selected 
Instrumentation
The Refrigerated CentriVap Concentrator was purchased from Labconco; the Inkubator +1000 and Unimax 1010 were purchased from Heidolph; and the Shimadzu UPLC-MS/MS system (Japan) was equipped with two LC-30AD solvent delivery pumps combined with gradient systems, a degasser model DGU-20A5, an autosampler model SIL-30AC, a column oven model CTO-20AC, and a UV detector model SPD-M20A. A Lux Celullose-1 (LC-1) column with a cellulose tris(3,5-dimetylphenylcarbamate) stationary phase, a Lux Cellulose-2 (LC-2) column with a cellulose tris(3-chloro-4methylphenylcarba-mate) stationary phase, a Lux Cellulose-3 (LC-3) column with a cellulose tris(4-methylbenzoate) stationary phase, a Lux Amulose-2 (LA-2) column with an amylose tris(5-chloro-2-methylphenylcarbamate) stationary phase, and a Guard Cartridge System model KJO-4282 were purchased from Phenomenex Co.
Chromatographic conditions
To achieve satisfactory chromatographic resolution of (R,S)-propranolol and its esters, the effects of both the composition, flow rate of the mobile phase, and the type of chiral stationary phase (CSP) were investigated. Five types of CSPs were tested in normal, reversed, and polar/organic phase. Finally, the Lux Cellulose-1 column was chosen as an optimal stationary phase for chromatographic separation in the polar/organic phase mode ( Figure 1 ). The mobile phase consisted of methanol/isopropanol/diethylamine/formic acid in a ratio of 99.
The chromatographic process was performed at 25°C. The detection was performed with the use of mass spectrometry in MRM mode. To determine the optical purity and enantioselectivity of the enantioselective acetylation, previously used equations based on peak areas from a chromatogram obtained by the chromatographic separation of (R,S)-propranolol and its derivatives were applied (10, 11) . Chemical acetylation of (R,S)-propranolol
The (R,S)-propranolol was acetylated according to the reported methodology (10, 12) with few modifications. Briefly, (R,S)-propranolol (0.02 g; 0.07 mmol) was refluxed with dichloromethane (20 mL), and acetyl chloride (8 µl; 0.076 mmol) was slowly added. Further, the reaction mixture was incubated at 30ᵒC for 2 h and successively washed with equal volumes of brine and saturated aqueous sodium bicarbonate. Next, the organic layer was collected and evaporated under vacuum to afford propranolol acetate. Finally, the resulting derivate of propranolol was used as a standard to establish an optimal chromatographic method for quantitative and qualitative determination of racemic propranolol and its acetylated form.
Enantioselective acetylation of (R,S)-propranolol
Enantioselective biotransformation of (R,S)-propranolol using vinyl acetate or isopropenyl acetate as the acetylating agent resulted in the production of N-acetyl-propranolol (Figure 2 ). Because the solubility of racemic propranolol is low in most organic solvents, the reaction was performed in 10 mL of the reaction medium. The reaction was performed with different solvents, e.g. acetonitrile, dichloromethane, diisopropyl ether, tert-butyl-methyl ether, chloroform, tetrahydrofuran, toluene, and racemic propranolol (3.0 mg), and vinyl acetate or isopropenyl acetate (2-10 µL) as the acetyl donor. The reaction was started by the addition of 10 mg of lipase in native form. The reaction mixture was shaken at 250 rpm at t = 37°C. The process of enantioselective acetylation was monitored using chiral stationary phases and a UPLC-MS/MS system. The samples were withdrawn at previously established time points (24, 48, 72, and 96 h) and then evaporated and re-dissolved in pure acetonitrile, filtered, and injected into the UPLC-MS/MS system.
results and discussion

Effect of acetylating agent
The effect of the acetylating agent was investigated in order to optimise the reaction conditions. The vinyl acetate as well as isopropenyl acetate were tested at different concentrations. The biocatalytic system consisted of toluene as a reaction medium, racemic propranolol (3.0 mg), lipase from Candida rugosa OF (10 mg), and an appropriate acetylating agent. The reaction was carried out at ambient temperature for 96 h. As shown in Figure 3 , the best reaction parameters were achieved by using isopropenyl acetate in the concentration 0.018 mmol (2 µL). Additionally, the use of vinyl acetate resulted in obtaining many by-products, which could not be identified; therefore, it was decided to use isopropenyl acetate in further steps of study optimisation in case of the solvent and lipase screening.
Effect of organic solvent
The effect of organic solvent on the properties of enzymatic kinetic resolution of racemic propranolol was investigated. It was decided to perform enantioselective biocatalysis in 10 mL of reaction medium due to the low solubility of racemic propranolol. Additionally, all of the tested solvents were organic because of the characteristics of enantioselective biotransformation, which relied on reaction of transesterification. The reaction mixture in that step of the study consisted of a different reaction medium, i.e. acetonitrile, chloroform, tetrahydrofuran, t-butyl-methyl ether, diisopropyl ether or toluene, lipase from Candida rugosa OF (10 mg), isopropenyl acetate (0.018 mmol) as an acetylating agent, and racemic propranolol (3.0 mg).
The catalytic properties of an enzyme are mainly affected by the hydrophobicity of the solvent. Therefore, the optimal choice of solvent as reaction medium is one of the most important parts of optimising reaction conditions for achievement of the best value of enantioselectivity. Among all tested solvents, only toluene proved to be suitable for performing the enantioselective acetylation of racemic propranolol, as shown in Table  1 . Even though the solubility of propranolol is higher in other solvents than toluene, these solvents are not suitable for the kinetic resolution of (R,S)-propranolol because the enantiomeric excess of product and enantioselectivity are low. Additionally, the use of toluene made it possible to obtain a high value of enantioselectivity, which was above 20. Based on abovementioned results, toluene as a reaction medium was selected for further investigation of lipase screening.
Screening of lipases
Commercially available lipases from Aspergilus niger, Burkholderia cepacia (BCL, SL), Candida antarctica (CAL-BY), Candida rugosa (MY, OF), Alcaigenes fecalis (QLM), Alcaigenes sp. (PL), and Pseudomonas strutzeri (TL) were tested for their catalytic properties in the enantioselective acetylation of racemic propranolol with isopropenyl acetate as an acetylating agent, and using toluene as the reaction medium. As shown in Table 2 , among all tested enzymes, the most satisfactory results were obtained for Candida rugosa lipases (OF, MY). However, it should be emphasised that the enantiomeric ratio and enantiomeric excess of product were higher in reactions using lipase conclusions
The reported results confirm that nine commercially available lipases have different effects on the kinetic resolution of (R,S)-propranolol. The type of lipase, the concentration of the acetylating agent, and the reaction medium have significant impacts on the efficiency of the catalyst system. The most effective conversion and the highest enantioselectivity were obtained using lipase from Candida rugosa (OF). Among all tested reaction mediums, toluene gave the highest enantioselectivity. The crucial point is that many different reaction factors influence the effectiveness of the enantioselective acetylation of b-blockers. Finally, the reaction mixture composed of Candida rugosa OF lipase, toluene as the reaction medium, and isopropenyl acetate as the acetylating agent made it possible to obtain enantiomerically pure (S)-propranolol acetate with ee p = 90.1%. However, it is necessary to optimise the methods for the kinetic resolution of chiral drugs to obtain enantiomerically pure products, and thus it is not possible to find a universal catalytic system for all syntheses because each enzymatic process requires an individual approach.
